{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:35:58Z","timestamp":1787070958330,"version":"build-2736575974"},"reference-count":12,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"Suppl 1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Diffuse large B cell Lymphomas (DLBCL) that co express C MYC and BCL 2 are known as \u2018double expressor lymphomas\u2019 and are believed to have a worse prognosis than other diffuse large B cell lymphomas. This was a study to assess the frequency of double expressor lymphomas in our cohort of DLBCL<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims and Objectives:<\/jats:title>\n                    <jats:p>The aims of this study were to assess the frequency of double expression of C MYC and BCL 2 in cases of DLBCL and to correlate the same with clinicopathological parameters including cell of origin, namely germinal centre type versus non germinal centre type.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>This was a retrospective observational study Immunostaining for MYC antibody and BCL2 were performed using the standard polymer\/DAB technique. 40% for MYC and 50% for BCL2 were taken as cut off values.Chi square analysis was used to compare the variables, and a p value of less than 0.05 was taken as statistically significant<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Of 40 cases studied, 11 (27.5%) were double expressors. There was no significant correlation of double expression with gender, site (nodal versus extra nodal), cell of origin namely germinal centre\/non germinal centre types and Ki67 index when compared to the other group which did not show double expression<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Immunohistochemistry is a useful technique to detect double expressor lymphomas which are known to have an aggressive course. Cell of origin did not show significant correlation with double expression in our study.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_587_21","type":"journal-article","created":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T09:25:21Z","timestamp":1681896321000},"page":"S145-S148","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["An immunohistochemical study of double-expressor lymphomas and its correlation with cell of origin"],"prefix":"10.4103","volume":"19","author":[{"given":"Anuradha","family":"Ananthamurthy","sequence":"first","affiliation":[{"name":"Department of Pathology, St John\u2019s Medical College, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,1,28]]},"reference":[{"key":"R1-20241021","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"key":"R2-20241021","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"key":"R3-20241021","first-page":"8","article-title":"Drug therapy for double-hit lymphoma","author":"Phuoc","year":"2019","journal-title":"Drugs in context"},{"key":"R4-20241021","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.1002\/cncr.31646","article-title":"Double hit and double expressors in lymphoma:Definition and treatment","volume":"124","author":"Riedell","year":"2018","journal-title":"Cancer"},{"key":"R5-20241021","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"R6-20241021","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.bbmt.2017.10.013","article-title":"Double-expressor lymphoma is associated with poor outcomes after allogeneic hematopoietic cell transplantation","volume":"24","author":"Kawashima","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"R7-20241021","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1182\/asheducation-2014.1.90","article-title":"Diagnosis of 'double hit'diffuse large B-cell lymphoma and B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma:When and how, FISH versus IHC","volume":"2014","author":"Swerdlow","year":"2014","journal-title":"Hematology"},{"issue":"Suppl 1","key":"R8-20241021","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1038\/modpathol.2012.178","article-title":"Aggressive B-cell lymphomas:How many categories do we need?","volume":"26","author":"Said","year":"2013","journal-title":"Mod Pathol"},{"key":"R9-20241021","first-page":"e13155","article-title":"Double-Expressor phenotype (BCL-2\/c-MYC Co-expression) of diffuse large B-Cell lymphoma and its clinicopathological correlation","volume":"13","author":"Hashmi","year":"2021","journal-title":"Cureus"},{"key":"R10-20241021","first-page":"ix90","article-title":"An attempt to predict double expresser DLBCL based on cell of origin and proliferative index (Ki-67):A prospective study from India","volume":"29","author":"Asati","year":"2018","journal-title":"Ann Oncol"},{"key":"R11-20241021","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s12288-019-01248-w","article-title":"Double hit and double expresser diffuse large b cell lymphoma subtypes:Discrete subtypes and major predictors of overall survival","volume":"36","author":"Mehta","year":"2020","journal-title":"Indian J Hematol Blood Transfus"},{"key":"R12-20241021","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1200\/JCO.2011.41.0985","article-title":"Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"30","author":"Johnson","year":"2012","journal-title":"J Clin Oncol"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_587_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:39:35Z","timestamp":1787067575000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_587_21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,28]]},"references-count":12,"journal-issue":{"issue":"Suppl 1","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_587_21","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,28]]},"assertion":[{"value":"2021-04-09","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-30","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}